The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01X | Other antineoplastic agents | |
4
|
L01XX | Other antineoplastic agents | |
5
|
L01XX87 |
| Active Ingredient |
|---|
|
Revumenib is a menin inhibitor that blocks the interaction of both wild-type lysine methyltransferase 2A (KMT2A) and KMT2A fusion proteins with menin. The binding of wild-type KMT2A or KMT2A fusion proteins with menin is involved in NPM1 mutated acute myeloid leukemias and KMT2A-rearranged acute leukemias, respectively, through activation of a leukemogenic transcriptional pathway. |
| Document | Type | Information Source | |
|---|---|---|---|
| REVUFORJ Film-coated tablet | MPI, US: SPL/PLR | FDA, National Drug Code (US) |